Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer

STATUS

Recruiting
days left to enroll

9
participants needed

90
sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Send

Updated on 19 February 2024

See if I qualify

cancer

estrogen

hysterectomy

breast cancer

potassium

direct bilirubin

gilbert's syndrome

taxane

oophorectomy

progesterone

tubal ligation

cervical cap

progesterone receptor

triple negative breast cancer

primary tumor

anthracyclines

male sterilization

bilateral oophorectomy

metformin

conjugated bilirubin

curative surgery

localized disease

anthracycline

preoperative chemotherapy

her2 gene amplification

gene amplification

serum fsh level

acidosis

HER2

fmd regimen

Summary

Glucose starvation and metformin have synergistic antitumor effects that are mediated through the concomitant inhibition of glycolysis and mitochondrial oxidative phosphorylation. The BREAKFAST trial will evaluate the antitumor activity of combining cyclic fasting-mimicking diet (FMD), which reproduces the in vitro effects of glucose starvation, plus/minus metformin with standard preperative anthracycline-taxane chemotherapy in patients with stage I-III TNBC

Description

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, and is associated with the lowest cure rates in the limited-stage disease setting, as well as with the lowest overall survival in the metastatic setting. Preclinical studies indicate that cycles of fasting or calorie-restricted, low-carbohydrate, low-protein diets, also known as fasting-mimicking diets (FMDs), have synergistic cytotoxic effects when combined with chemotherapy agents, such as doxorubicin or cisplatin, in several in vitro and in vivo tumor models, including murine TNBC models. More recently, intermittent fasting has demonstrated highly synergistic antitumor effects when combined with metformin; of note, these effects are mediated through the concomitant inhibition of glycolysis (via fasting-induced hypoglycemia) and metformin-induced inhibition of mitochondrial oxidative phosphorylation (OXPHOS). Finally, small reports published so far indicate that cyclic fasting and FMDs are well tolerated in cancer patients, and can be safety combined with standard antitumor treatments.

Based on these data, the BREAKFAST trial was designed to investigate the antitumor activity of cyclic FMD, alone or in combination with metformin, in patients with localized TNBC. In this study, 90 patients with stage I-III TNBC will be randomized in a 1:1 ratio to receive approximately 6 months of standard preoperative anthracycline plus taxane chemotherapy in combination with eight triweekly cycles of 5-day FMD (Arm A), or the same chemotherapy-FMD regimen plus daily metformin (Arm B). The primary objective of the study is to demonstrate that one or both experimental treatments increase the rate of pCR from 45% (historical data) to 65%

Details

Condition	Breast Cancer, Breast Cancer, Breast Cancer - HER2 Positive
Age	18years - 75years
Treatment	Metformin, Fasting-mimicking diet, Preoperative chemotherapy
Clinical Study Identifier	NCT04248998
Sponsor	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	b'Patients eligible for inclusion in this study must meet all of the following criteria:'
	b'Female sex'
	b'Age \\u2265 18 and \\u2264 75 years.'
	b'Evidence of a personally signed and dated informed consent document (ICD)'
	b'indicating that the patient has been informed of all pertinent aspects of the'
	b'tudy before enrollment'
	b'Willingness and ability to comply with the prescribed FMD regimen, metformin'
	b'intake, the scheduled visits, treatment plans, laboratory tests and other'
	b'procedures.'
	b'Histologically confirmed diagnosis of invasive TNBC candidate to neoadjuvant'
	b'chemotherapy and subsequent curative surgery. On the basis of International'
	b'Guidelines, TNBC is defined by absent or minimal (<1%) expression of oestrogen'
	b'and progesterone receptors at IHC, and absence of HER2 over-expression or'
	b'amplification, as defined as an IHC score of 0, 1+, or an IHC score of 2+ with in'
	b'itu hybridization (ISH) analysis excluding HER2 gene amplification.'
	b'Patients with localized disease (clinical stage I-III according to TNM). Patients'
	b'with Stage I TNBC will be included only if the primary tumor is at least 10 mm in'
	b'greatest dimension (clinical T1c as determined through baseline MRI assessment).'
	b'Presence of an Eastern Cooperative Oncology Group (ECOG) performance status 0 or'
	b''
	b'Presence of adequate bone marrow and organ function as defined by the following'
	b'laboratory values:'
	b'ANC \\u2265 1.5 x 103/l'
	b'platelets \\u2265 100 x 103/l'
	b'hemoglobin \\u2265 9.0 g/dl'
	b'calcium (corrected for serum albumin) within normal limits or \\u2264 grade 1'
	b'according to NCI-CTCAE version 5.0 if not clinically significant'
	b'potassium within the normal limits, or corrected with supplements'
	b'creatinine < 1.5 ULN'
	b'blood uric acid < 10 mg/dl'
	b'ALT and AST \\u2264 2 x ULN'
	b'total bilirubin < 1.5 ULN except for patients with Gilbert syndrome who may'
	b'only be included if the total bilirubin is < 3.0 x ULN or direct bilirubin <'
	b'5 x ULN'
	b'Fasting glucose \\u2264 250 mg/dl.'
	b'Female patients of childbearing potential must agree to sexual abstinence or to'
	b'use two highly effective methods of contraception throughout the study and for at'
	b'least six months after the end of the FMD. Abstinence is only acceptable if it is'
	b'in line with the preferred and usual lifestyle of the patient. Examples of'
	b'contraceptive methods with a failure rate of < 1% per year include tubal'
	b'ligation, male sterilization, hormonal implants, established, proper use of'
	b'combined oral or injected hormonal contraceptives, and certain intrauterine'
	b'devices. Alternatively, two methods (e.g., two barrier methods such as a condom'
	b'and a cervical cap) may be combined to achieve a failure rate of < 1% per year.'
	b'Barrier methods must always be supplemented with the use of a spermicide. A'
	b'patient is of childbearing potential if, in the opinion of the Investigator, she'
	b'is biologically capable of having children and is sexually active.'
	b'Female patients are not of childbearing potential if they meet at least one of'
	b'the following criteria:'
	b'Have undergone a documented hysterectomy and/or bilateral oophorectomy'
	b'Have medically confirmed ovarian failure'
	b'Achieved post-menopausal status, defined as: \\u2265 12 months of'
	b'non-therapy-induced amenorrhea or surgically sterile (absence of ovaries)'
	b"and have a serum FSH level within the laboratory's reference range for"
	b'postmenopausal females.'
Exclusion Criteria
	b'Patients eligible for this study must not meet any of the following criteria:'
	b'Prior systemic treatment for breast cancer or other malignancies within 5 years'
	b'of treatment enrollment.'
	b'Prior treatment with anthracyclines'
	b'Diagnosis of other malignancies in advanced stages (unresectable, locally'
	b'advanced or metastatic), or that required systemic (neo)adjuvant chemotherapy in'
	b'the previous 5 years. Other malignancies diagnosed more than 5 years before the'
	b'diagnosis of breast cancer must have been radically treated without evidence of'
	b'relapse at the moment of patient enrollment in the trial.'
	b'Body mass index (BMI) < 20 kg/m2.'
	b'History of alcohol abuse.'
	b'Non-intentional weight loss \\u2265 5% in the previous 3 months, unless the patient has'
	b'a BMI > 22 kg/m2 and weight loss has been lower than 10% at the time of'
	b'enrollment in the study; or non-intentional weight loss of \\u2265 10% in the previous'
	b'3 months, unless the patients has a BMI > 25 kg/m2 and weight loss has been lower'
	b'than 15% at the time of the enrollment in the study. In both cases, weight must'
	b'have been stable for at least one month before study enrollment.'
	b'Active pregnancy or breast feeding.'
	b'Known active B or C hepatitis or human immunodeficiency virus (HIV) infection, or'
	b'occasional finding of active hepatitis B/C infection during screening tests'
	b'before chemotherapy initiation, as defined as positive polymerase chain reaction'
	b'(PCR) testing for HBV-DNA and HCV-RNA and qualitative PCR for HIV-RNA, or'
	b'requiring active treatment at study enrollment.'
	b'Serious infections in the previous 4 weeks before the FMD initiation, including,'
	b'but not limited to, potential hospitalizations for complications of infections,'
	b'bacteriemia or serious pneumonitis.'
	b'Active autoimmune diseases requiring systemic treatments (e.g. systemic steroids'
	b'or immune suppressants).'
	b'Active chronic therapy with systemic steroids at a dose \\u2265 10 mg per day of'
	b'prednisone or equivalent at study enrollment.'
	b'Known recent diagnosis of hypothyroidism requiring systemic replacement hormonal'
	b'therapy and without stabilization of hormonal profile (fT3, fT4 and TSH within'
	b'the normal range).'
	b'Diagnosis of type 1 or 2 diabetes mellitus requiring pharmacologic therapy'
	b'(including, but not limited to, insulin, secretagogues and metformin). A'
	b'diagnosis of type 2 diabetes mellitus not requiring pharmacological treatments'
	b'based on the judgment of a diabetologist, is compatible with patient enrollment'
	b'in the trial.'
	b'Active gastric or intestinal ulcerative disease, uncontrolled nausea, vomiting,'
	b'diarrhea, malabsorption syndrome, small intestine resection.'
	b'Anamnesis of clinically significant heart disease including:'
	b'angina pectoris, coronary bypass, symptomatic pericarditis, myocardial'
	b'infarction in the previous 12 months from the beginning of experimental'
	b'therapy;'
	b'congestive heart failure (NYHA III-IV).'
	b'Anamnesis of clinically meaningful cardiac arrhythmias, such as ventricular'
	b'tachycardia, chronic atrial fibrillation, complete bundle branch block, high'
	b'grade atrio-ventricular block like bi-fascicular block, type II Mobitz and third'
	b'grade atrio-ventricular block, nodal arrhythmias, supra-ventricular arrhythmia.'
	b'Left ventricular ejection fraction lower than 50% at the cardiac scan with'
	b'radionuclides or at echocardiography.'
	b'Previous episodes of symptomatic hypotension leading to loss of consciousness.'
	b'Baseline plasma fasting glucose \\u2264 60 mg/dL.'
	b'Medical or psychiatric comorbidities rendering the patient not candidate to the'
	b"clinical trial, according to the investigator's judgement."
	b'Other cardiac, liver, lung or renal comorbidities, not specified in the previous'
	b'risk of lactic acidosis.'

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

progesterone receptor

triple negative breast cancer

primary tumor

anthracyclines

male sterilization

bilateral oophorectomy

preoperative chemotherapy

her2 gene amplification

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer